tickrz reports
tickrz rank
D
Abbott Laboratories (ABT)
Healthcare | Health Services
51.57  -1.02%
FACTOR RANKINGSFACTOR SCREENER 
tickrz RankD / 379Warren Buffett RankD / 435
Pure Value RankD / 376Dividend RankD / 408
Moat RankD / 374Financial Strength RankB / 183
Growth RankD / 460Momentum RankB / 195
ABT vs HEALTH SERVICES SECTOR & S&P 500
VALUATION
ABTSECTORS&P 500
P/E RATIO77.332.119.28
EV/EBITDA RATIO19.121711.77
P/S RATIO3.833.62.03
P/B RATIO2.865.53.09
QUALITY
RETURN ON EQUITY4.45%15.64%13.82%
RETURN ON CAPITAL3.78%50.61%10.04%
NET MARGIN5.06%8.18%9.76%
DIVIDEND ANALYSIS
DIVIDEND YIELD
2.04%
PAYOUT RATIO144.49%
3 YR DIVIDEND GROWTH17.75%
FINANCIAL STRENGTH
PIOTROSKI F SCORE
5 OUT OF 9
DEBT-TO-EQUITY76%
INTEREST COVERAGE9.97x
CURRENT RATIO2.94
GROWTH
5 YR EPS GROWTH-20.96%
5 YR SPS GROWTH-11.7%
5 YR BPS GROWTH-2.17%
About tickrz
Key Concepts
Great Investors
tickrz Report
tickrz rank D / 379
Abbott Laboratories receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
value
pure value ranking D / 376Warren Buffett ranking D / 435
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Abbott Laboratories's valuation score is comprised of a P/E ratio of 77.3x, a P/B ratio of 2.9x, a P/S ratio of 3.8x, and an EV/EBITDA ratio of 19.1x. Abbott Laboratories ranks 376 out of the S&P 500 constituents on valuation--a relatively weak score.Abbott Laboratories ranks 435 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Abbott Laboratories is probably not for you.

quality
moat D / 374financial strength B / 183
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is weak. Its position within the Healthcare sector appears to be weak. Either the dynamics of its sector place it in a difficult position or management's executition is to blame for its disappointing performance.Abbott Laboratories has a Piotroski F Score of 5 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 9.97x, a debt/equity ratio of 76% and a Moat Rank of 374 translate to an average Financial Strength score.


momentum B / 195
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 18.73% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 195. Based on its 12 month stock performance, Abbott Laboratories will not appeal to momentum investors.

yield D / 408
value + yield
Shares currently yield 2.04%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, Abbott Laboratories ranks 408 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

growth D / 460
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the bottom third of S&P500 companies. Its -21% 5 year annualized EPS growth, -11.7% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of -2.2% speak to its relatively poor ranking.

Abbott Laboratories (ABT)
Healthcare | Health Services
51.57  -1.02%


tickrz rank
D
VALUATION RATIOS
P/E Ratio77.3x
P/B Ratio2.86x
P/S Ratio3.83x
EV/EBITDA Ratio19.12x
DIVIDEND ANALYSIS
DIVIDEND YIELD
2.04%
PAYOUT RATIO144.49%
3 YR DIVIDEND GROWTH17.75%
FINANCIAL STRENGTH
PIOTROSKI F SCORE
5 OUT OF 9
DEBT-TO-EQUITY76%
INTEREST COVERAGE9.97x
CURRENT RATIO2.94
MOAT
ROE4.45%
ROIC3.78%
Net Margin5.06%
GROWTH
5 YR EPS GROWTH-20.96%
5 YR SPS GROWTH-11.7%
5 YR BPS GROWTH-2.17%

TICKRZ RANK
Abbott Laboratories receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Abbott Laboratories's valuation score is comprised of a P/E ratio of 77.3x, a P/B ratio of 2.9x, a P/S ratio of 3.8x, and an EV/EBITDA ratio of 19.1x. Abbott Laboratories ranks 376 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
Abbott Laboratories ranks 435 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Abbott Laboratories is probably not for you.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is weak. Its position within the Healthcare sector appears to be weak. Either the dynamics of its sector place it in a difficult position or management's executition is to blame for its disappointing performance.

FINANCIAL STRENGTH
Abbott Laboratories has a Piotroski F Score of 5 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 9.97x, a debt/equity ratio of 76% and a Moat Rank of 374 translate to an average Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 18.73% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 195. Based on its 12 month stock performance, Abbott Laboratories will not appeal to momentum investors.

VALUE + YIELD
Shares currently yield 2.04%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, Abbott Laboratories ranks 408 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the bottom third of S&P500 companies. Its -21% 5 year annualized EPS growth, -11.7% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of -2.2% speak to its relatively poor ranking.